#USA #AI Technology #Clinical Trials #Ryght AI #Laguna Beach, California

Ryght AI Unveils Expert Scientific Advisory Board to Drive Clinical Trial Innovations

In a significant development towards revolutionizing clinical trials, Ryght AI has announced the formation of its inaugural Scientific Advisory Board (SAB). This board is composed of preeminent leaders in various medical disciplines, particularly in oncology, hematology, and healthcare technology. Their combined expertise aims to guide Ryght AI through its next phase of innovation, enhancing the efficiency of clinical trials on a global scale.

A Game Changer in Clinical Research

Ryght AI, renowned for its groundbreaking AI Site Twin technology, is on a mission to transform how clinical trial sites are selected and activated. By establishing the SAB, the company seeks to leverage the distinguished insights of its members to overcome the common challenges faced during clinical trials. According to Dr. Chadi Nabhan, Chief Medical Officer of Ryght AI and SAB chair, the board will play a crucial role in steering the company's strategic initiatives, ensuring that Ryght's technologies are aligned with the real-world needs of the medical community.

Notable Members of the SAB

The SAB features an impressive list of medical professionals:

• - Dr. Manmeet Ahluwalia – Chief of Medical Oncology at Baptist Health Miami Cancer Institute.
• - Dr. Neeraj Agarwal – Endowed Chair of Cancer Research at Huntsman Cancer Institute.
• - Dr. Tanios Bekaii-Saab – Chairman of Hematology/Medical Oncology at Mayo Clinic.
• - Dr. Razelle Kurzrock – Founding Director at the Medical College of Wisconsin.

These experts, alongside others from diverse specialties, will contribute not just their knowledge but also engage in collaborative research with sponsors, thus ensuring the pace of innovation aligns with the clinical needs of patients.

The Role of AI in Modern Clinical Trials

The modern landscape of clinical trials is rife with complexity. Traditional methodologies often rely on static data that limit the agility needed to adapt to unforeseen changes during trial operations. This is where Ryght AI's platform stands out. The utilization of AI Site Twins provides dynamic digital models of research sites, significantly enhancing the selection process for trial locations and improving overall operational performance.

Dr. Manmeet Ahluwalia emphasized the importance of rapid adaptation in clinical research. He stated, “The challenges posed by conventional clinical trials call for innovative solutions that harness technology to automate intricate processes.” By employing Ryght AI's generative platform, trial sponsors can not only accelerate patient recruitment but also streamline workflow complexities, thereby enhancing the overall speed to market for new therapies.

Strategic Vision for the Future

As the SAB collaborates closely with Ryght's leadership and research teams, it will focus on several key areas:

• - Accelerating the scaling of Ryght AI’s research capabilities.
• - Supporting strategic decision-making processes and guiding product development.
• - Ensuring high scientific rigor in all projects.
• - Facilitating partnerships with academic and research institutions to broaden the impact of their work.

According to Razelle Kurzrock, the board's input will be vital to improving the technologies that contribute to faster recruitment and trial efficacy, essentially minimizing delays that often plague the research and development phases.

Conclusion

Ryght AI’s commitment to ethical AI practices and a focus on tangible societal impacts shines through with the establishment of its SAB. By tapping into the unparalleled expertise of its members, the company is poised to redefine the landscape of clinical trials, making significant strides towards the faster delivery of life-saving treatments to patients around the world. For an in-depth exploration of their offerings and insights on AI in clinical research, Ryght AI encourages interested parties to visit their website at www.ryght.ai.